Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis
Publication: Annals of Internal Medicine
Volume 166, Number 9
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Abstract
Background:
Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk.
Purpose:
To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.
Data Sources:
PubMed and the Cochrane Central Register of Controlled Trials from December 2006 through December 2016.
Study Selection:
Paired reviewers independently screened abstracts and full-text articles for English-language, randomized, controlled trials that had at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and reported on BMD, fractures, or safety (mortality and adverse events).
Data Extraction:
Two reviewers serially abstracted data and independently assessed risk of bias and graded the strength of evidence (SOE).
Data Synthesis:
There were 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage 3 to 5 CKD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials). Evidence showed that bisphosphonates may slow loss of BMD among transplant recipients (moderate SOE), but their effects on fractures and safety in transplant recipients and others with CKD are unclear. Raloxifene may prevent vertebral fractures but may not improve BMD (low SOE). Effects of teriparatide and denosumab on BMD and fractures are unclear (very low SOE), and these medications may increase risk for some safety outcomes.
Limitation:
Unclear rigor of evidence, possible reporting biases, and scant evidence among patients with stage 3 to 5 CKD.
Conclusion:
Effects of osteoporosis medications on BMD, fracture risk, and safety among patients with CKD are not clearly established.
Primary Funding Source:
Kidney Disease: Improving Global Outcomes.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States. Atlanta: Centers for Disease Control and Prevention; 2016. Accessed at www.cdc.gov/ckd on 10 October 2016.
2.
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12. [PMID: 12500213]
3.
Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165:473-81. [PMID: 27479614]. doi: 10.7326/M16-0273
4.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009:S1-130. [PMID: 19644521] doi: 10.1038/ki.2009.188
5.
Zhang R, Chouhan KK. Metabolic bone diseases in kidney transplant recipients. World J Nephrol. 2012;1:127-33. [PMID: 24175250] doi: 10.5527/wjn.v1.i5.127
6.
Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396-9. [PMID: 10886587]
7.
Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM. Hip fracture in patients with non–dialysis-requiring chronic kidney disease. J Bone Miner Res. 2016;31:1803-9. [PMID: 27145189] doi: 10.1002/jbmr.2862
8.
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115-21. [PMID: 11096034]
9.
Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358-66. [PMID: 16929251]
10.
Naylor KL, Li AH, Lam NN, Hodsman AB, Jamal SA, Garg AX. Fracture risk in kidney transplant recipients: a systematic review. Transplantation. 2013;95:1461-70. [PMID: 23594857] doi: 10.1097/TP.0b013e31828eead8
11.
Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11:450-7. [PMID: 11557176]
12.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004;15:108-12. [PMID: 14598026]
13.
Marques A, Lourenço Ó, da Silva JA; Portuguese Working Group for the Study of the Burden of Hip Fractures in Portugal. The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. Osteoporos Int. 2015;26:2623-30. [PMID: 25986386] doi: 10.1007/s00198-015-3171-5
14.
Lin ZZ, Wang JJ, Chung CR, Huang PC, Su BA, Cheng KC, et al. Epidemiology and mortality of hip fracture among patients on dialysis: Taiwan National Cohort Study. Bone. 2014;64:235-9. [PMID: 24780875] doi: 10.1016/j.bone.2014.04.017
15.
Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014;85:166-73. [PMID: 23903367] doi: 10.1038/ki.2013.279
16.
Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes Controversies Conference. Kidney Int. 2015;87:502-28. [PMID: 25651364] doi: 10.1038/ki.2014.425
17.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. [PMID: 19631508] doi: 10.1016/j.jclinepi.2009.06.005
18.
Higgins J, Green S, eds. Cochrane Handbook for Systemic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration. 2011.
19.
Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693-710. [PMID: 12939780]
20.
Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med. 2014;160:267-70. [PMID: 24727843]. doi: 10.7326/M13-2886
21.
Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-75. [PMID: 15116347]
22.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
23.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101. [PMID: 7786990]
24.
Egger M, DaveySmith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. [PMID: 9310563]
25.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
26.
Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14:2669-76. [PMID: 14514747]
27.
Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis. 2009;53:856-65. [PMID: 19393473] doi: 10.1053/j.ajkd.2008.11.036
28.
Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res. 2007;22:503-8. [PMID: 17243862]
29.
Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010;56:57-68. [PMID: 20347511] doi: 10.1053/j.ajkd.2009.12.039
30.
Smerud KT, Dolgos S, Olsen IC, Åsberg A, Sagedal S, Reisæter AV, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant. 2012;12:3316-25. [PMID: 22946930] doi: 10.1111/j.1600-6143.2012.04233.x
31.
Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S, et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation. 2010;89:1476-81. [PMID: 20393402] doi: 10.1097/TP.0b013e3181dc13d0
32.
Haghverdi F, Farbodara T, Mortaji S, Soltani P, Saidi N. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J Kidney Dis. 2014;8:461-6. [PMID: 25362221]
33.
Hernández E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003;63:2269-74. [PMID: 12753317]
34.
Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE; MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19:1430-8. [PMID: 18400939] doi: 10.1681/ASN.2007050555
35.
Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18:59-68. [PMID: 17013567]
36.
Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829-35. [PMID: 21491487] doi: 10.1002/jbmr.403
37.
Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16:1882-91. [PMID: 26713403] doi: 10.1111/ajt.13692
38.
Sánchez-Escuredo A, Fuster D, Rubello D, Muxí A, Ramos A, Campos F, et al. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nucl Med Commun. 2015;36:815-8. [PMID: 25856225] doi: 10.1097/MNM.0000000000000316
39.
Kan SL, Ning GZ, Chen LX, Zhou Y, Sun JC, Feng SQ. Efficacy and safety of bisphosphonates for low bone mineral density after kidney transplantation: a meta-analysis. Medicine (Baltimore). 2016;95:e2679. [PMID: 26844505] doi: 10.1097/MD.0000000000002679
40.
Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant. 2016;30:1090-6. [PMID: 27327448] doi: 10.1111/ctr.12792
41.
Versele EB, Van Laecke S, Dhondt AW, Verbeke F, Vanholder R, Van Biesen W, et al. Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transpl Int. 2016;29:153-64. [PMID: 26369899] doi: 10.1111/tri.12691
42.
Naylor KL, Zou G, Leslie WD, Hodsman AB, Lam NN, McArthur E, et al. Risk factors for fracture in adult kidney transplant recipients. World J Transplant. 2016;6:370-9. [PMID: 27358782] doi: 10.5500/wjt.v6.i2.370
43.
Maravic M, Ostertag A, Torres PU, Cohen-Solal M. Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int. 2014;25:159-65. [PMID: 23835863] doi: 10.1007/s00198-013-2435-1
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 166 • Number 9 • 2 May 2017
Pages: 649 - 658
History
Published online: 11 April 2017
Published in issue: 2 May 2017
Keywords
Copyright
© 2017 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med.2017;166:649-658. [Epub 11 April 2017]. doi:10.7326/M16-2752
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med.2017;166:649-658. [Epub 11 April 2017]. doi:10.7326/M16-2752
View More
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Comments
0 Comments